According to the Kidney Disease Outcomes Quality Initiative (KDOQI) guideline, only several oral hypoglycemic agents (OHA) kinds can be administered in dialysis patients, including sulfonylurea (SU, such as glipizide and gliclazide), meglitinide (repaglinide), thiazolidinediones (TZD), and dipeptidyl-peptidase IV (DPP-4) inhibitors [10]. This evidence concerns the gene DPP4 and kidney disorder.